A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to cancer cells and not normal cells, potentially allowing clinicians to ...
Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback